Company news

BioVie Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BioVie Inc. Announces Pricing of Public Offering

September 22, 2024

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

September 15, 2024

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

September 2, 2024

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

August 26, 2024

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

August 12, 2024

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

August 7, 2024

BioVie Inc. Announces Reverse Stock Split

August 5, 2024

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

June 24, 2024

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

June 19, 2024

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

June 11, 2024

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

June 3, 2024

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

May 21, 2024

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

April 28, 2024

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

April 24, 2024

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

April 17, 2024

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

March 10, 2024

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzh...

February 29, 2024

BioVie Inc. Announces Proposed Public Offering of Common Stoc

February 29, 2024

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

November 28, 2023

BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

November 12, 2023

BioVie to Participate in the Truist Securities BioPharma Symposium

November 1, 2023

BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8: 00 AM ET

October 29, 2023

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023

October 25, 2023

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

October 24, 2023

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD

October 18, 2023

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

September 25, 2023

BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation

September 19, 2023

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

September 18, 2023

BioVie chief social impact officer sees major need for Alzheimer’s support and research

September 11, 2023

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

September 10, 2023

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

September 6, 2023

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

August 30, 2023

BioVie Set to Join the Russell 2000® and Russell 3000® Indexes

June 22, 2023

BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

April 16, 2023

BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023

March 20, 2023

BioVie Announces Registration Details for "BioVie Day" Webinar

March 13, 2023

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

March 12, 2023

BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo

March 5, 2023

BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease

March 1, 2023

BioVie Announces “BioVie Day” to be held March 23, 2023

February 20, 2023

BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

December 5, 2022

BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

December 4, 2022

BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients

November 28, 2022

BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

October 18, 2022

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

June 22, 2022

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

January 19, 2022

BioVie Announces Partnership with the American Liver Foundation

December 8, 2021

BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

November 30, 2021

BioVie Announces the Appointment of a New Chief Medical Officer

October 31, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 24 decks. Every deck is listed under its year.